Vestor Capital LLC Purchases 5,212 Shares of Guardant Health, Inc. $GH

Vestor Capital LLC lifted its position in shares of Guardant Health, Inc. (NASDAQ:GH) by 27.2% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 24,381 shares of the company’s stock after acquiring an additional 5,212 shares during the quarter. Vestor Capital LLC’s holdings in Guardant Health were worth $4,349,000 at the end of the most recent quarter.

Several other large investors have also recently bought and sold shares of GH. MCF Advisors LLC grew its stake in shares of Guardant Health by 755.0% during the 2nd quarter. MCF Advisors LLC now owns 171 shares of the company’s stock worth $26,000 after purchasing an additional 151 shares during the period. NFSG Corp acquired a new stake in shares of Guardant Health in the 3rd quarter worth approximately $33,000. Fulcrum Asset Management LLP acquired a new stake in shares of Guardant Health in the 3rd quarter worth approximately $37,000. Ascentis Independent Advisors purchased a new position in Guardant Health in the 1st quarter valued at approximately $38,000. Finally, Hollencrest Capital Management purchased a new position in Guardant Health in the 1st quarter valued at approximately $41,000. Hedge funds and other institutional investors own 92.60% of the company’s stock.

Insider Activity at Guardant Health

In other news, Director Steve Krognes sold 6,674 shares of the business’s stock in a transaction on Wednesday, September 16th. The shares were sold at an average price of $175.74, for a total transaction of $1,172,888.76. Following the completion of the transaction, the director owned 7,906 shares of the company’s stock, valued at approximately $1,389,400.44. The trade was a 45.78% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, insider Terilyn Monroe sold 46,300 shares of the firm’s stock in a transaction that occurred on Wednesday, August 12th. The shares were sold at an average price of $165.12, for a total value of $7,645,056.00. Following the completion of the sale, the insider owned 22,979 shares in the company, valued at approximately $3,794,292.48. This represents a 66.83% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders have sold 99,455 shares of company stock valued at $16,752,081. Company insiders own 5.60% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have commented on GH shares. Morgan Stanley boosted their target price on Guardant Health from $185.00 to $200.00 and gave the stock an “overweight” rating in a research report on Monday, October 12th. Stephens raised their target price on shares of Guardant Health from $170.00 to $195.00 and gave the company an “overweight” rating in a report on Tuesday, August 4th. Sanford C. Bernstein restated an “outperform” rating and set a $210.00 target price on shares of Guardant Health in a research report on Thursday, September 10th. Royal Bank Of Canada upped their price target on shares of Guardant Health from $185.00 to $200.00 and gave the company an “outperform” rating in a report on Friday, July 31st. Finally, UBS Group increased their price target on shares of Guardant Health from $175.00 to $225.00 and gave the company a “buy” rating in a research report on Wednesday, September 9th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-four have issued a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $191.00.

Guardant Health Trading Up 5.2%

NASDAQ GH opened at $158.79 on Tuesday. Guardant Health, Inc. has a 52 week low of $74.55 and a 52 week high of $191.05. The stock has a market cap of $21.31 billion, a P/E ratio of -43.15 and a beta of 1.67. The company’s fifty day simple moving average is $169.26 and its 200-day simple moving average is $132.22.

Guardant Health (NASDAQ:GH) last released its quarterly earnings results on Thursday, November 5th. The company reported ($0.29) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.75) by $0.46. The company had revenue of $360.98 million for the quarter, compared to analyst estimates of $350.72 million. During the same period in the previous year, the business posted ($0.74) EPS. The firm’s quarterly revenue was up 36.1% compared to the same quarter last year. On average, research analysts expect that Guardant Health, Inc. will post -3.08 EPS for the current fiscal year.

About Guardant Health

Guardant Health is a precision oncology company that develops blood- and tissue-based tests to help guide cancer care. Founded in 2012 by Helmy Eltoukhy and AmirAli Talasaz, the company focuses on using genomic information to support cancer detection, treatment selection and disease monitoring.

Its products include Guardant360 tests, which analyze tumor-related genetic changes to help inform treatment decisions, and Guardant Reveal, which is designed to detect residual or recurring cancer after treatment.